Davide Capodanno/X
Jul 8, 2025, 07:56
AUREA – No Added Benefit of Short-Term OAC Post-TAVI in Patients Without OAC Indication
Davide Capodanno, Professor of Cardiology at University of Catania, Italy has posted on X:
“In the randomized, open-label AUREA trial, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism in patients without an indication for OAC. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol.”

You can read the Full Article here.
Explore more on Hemostasis Today.
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US
-
Jul 11, 2026, 21:41Bianca Constantin: Don’t Miss the ISTH Early Career Committee Activities
-
Jul 11, 2026, 21:38Fateme Babaha: Don’t Miss Your Favorite ISTH 2026 Sessions
-
Jul 11, 2026, 21:11Farjah Algahtani: Learning, Sharing, and Collaborating at ISTH 2026
-
Jul 11, 2026, 19:56Louise St. Germain Bannon: A Fantastic Start to ISTH 2026 and the Future of Thrombosis Research
-
Jul 11, 2026, 19:38Lynn Kloeckner: Recognizing Kirsten Lacine’s Impact on the Stroke Survivor Journey
-
Jul 11, 2026, 19:19Rens De Groot: New Proteomic Evidence Reveals Early Hemolysis During ADAMTS13 Relapse in Immune TTP
-
Jul 11, 2026, 19:01Laurent Bertoletti: Honoring the Legacy of Guy Meyer and the INNOVTE Network at ISTH 2026